Phase II Flub for Peregrine
September 24, 2012 | A week after releasing favorable Phase II results for the novel vascular-targeting immunotherapy for non-small cell lung cancer, bavituximab, study sponsor Peregrine Pharmaceuticals has announced "major discrepancies" in the trial. Peregrine blames the research oversight team in charge of the trial (they were blinded), but the announcement still resulted in plummeting Peregrine stock. Cancer Grace
